Suzuki et al. demonstrated an increase in GLUT1 expression and glucose uptake in EGFR-TKI resistant NSCLC cells and ablation of GLUT1 re-sensitizes resistant cells to gefitinib [8]. Here, SLC2A1 is linked to non-small cell lung carcinoma.